TLR9 and metabolic dysfunction-associated steatohepatitis: The liver-gut-adipose-centric bioavailability of this mode of delivering TLR9 antagonism would seem to have an advantage in keeping the highest free drug concentrations limited to those organs most involved in the pathogenesis of NASH disease (252).